

List of Beremans reports available for purchase, in reverse order of date:

**UK/Ireland biotechnology sector: clinical phase drug development pipeline. Beremans Ltd, Sep 2011.**

This report identifies all UK / Ireland biotechnology companies with drug candidates that have entered clinical trials. All clinical phase drug candidates being developed by these companies are listed, both by clinical trial phase and by the category of disease (ICD-10) that they are intended to address. A table is provided containing a brief outline of each company (public/private status, geographic location, web address, focus of activity, pipeline summary). Therefore, the report contains information likely to be of use to, *inter alia*, parties contemplating licensing, merger or acquisition activity in the UK/Ireland biotechnology sector, or parties intending to provide products or services to companies in this sector. The report may be purchased [here](#).

**Malaria vaccines: commercial prospects and landscape analysis: Beremans Ltd, July 2010.**

This report includes an examination of the clinical need for a malaria vaccine (nature of disease, independent estimation of global incidence, identification and quantification of at-risk populations worldwide); an outline of the scientific / technological background (including key issues in malaria vaccine development); an assessment of the competitive environment, including the competitive positioning of clinical-stage vaccine candidates, and brief notes on commercial and non-commercial bodies linked to malaria vaccine development; quantification and 2020 projections of total potential end-users of a malaria vaccine (namely, travellers from >20 developed economies to regions of malaria transmission; private sector users in malaria transmission regions; public sector users in malaria transmission regions; and a provisional outline analysis of the military market); likely prices for a malaria vaccine in different markets; and 2020 revenue projections for a malaria vaccine, broken down by private sector sales in the developed world, private sector sales in the developing world, and public sector sales in the developing world. The report may be purchased [here](#).

**Dengue vaccines: commercial prospects and landscape analysis: Beremans Ltd, November 2009.**

This report includes an examination of the clinical need for a dengue vaccine (nature of disease, independent estimation of global incidence, identification and quantification of at-risk populations worldwide), an outline of the scientific / technological background (including key issues in dengue vaccine development), an assessment of the competitive environment, quantification and 2020 projections of total potential end-users of a dengue vaccine (namely, travellers from all developed economies to all regions of dengue transmission; private sector users in dengue transmission regions; and public sector users in dengue transmission regions), and 2020 revenue projections for a dengue vaccine, broken down by private sector sales in the developed world, private sector sales in the developing world, and public sector sales in the developing world. The report may be purchased [here](#).

**Cardiotoxicity screening: issues, technologies and solutions for the future: Beremans Ltd / Insight Pharma, April 2008.**

This report identifies and discusses methods, products and services designed to identify cardiotoxic compounds before they reach the market; discusses the current and possible future regulatory environment; outlines main commercial competitors; and suggests broad types of commercial opportunity and future M&A activity in this subsector. The primary focus is on identification of proarrhythmia, but some discussion is provided on identification of other forms of cardiotoxicity. The report may be purchased [here](#).